Methods
In the four tertiary centers in Turkey, the patients to whom the new oral anticoagulants (dabigatrane etexilate and rivaroxaban) have been prescribed have been identified. The contact phone numbers and the overall clinical information of the patients have been revealed using the medical records of the patients. The patients were questioned in a phone call. The clinical events which occurred during the period of the drug usage were recorded.
Methods
In the four tertiary centers in Turkey, the patients to whom the new oral anticoagulants (dabigatrane etexilate and rivaroxaban) have been prescribed have been identified. The contact phone numbers and the overall clinical information of the patients have been revealed using the medical records of the patients. The patients were questioned in a phone call. The clinical events which occurred during the period of the drug usage were recorded.
Results
201 patients receiving the treatment of dabigatran or rivoraxaban were detected. To the 183 of these patients could be reached using their contact information. 95 patients were using dabigatrane and 88 patients were using rivoraxaban. The average treatment-duration of dabigatran was 17 ± 8 months and the mean treatmet-duration of rivoraxaban was found to be 17 ± 7.5 months. There were no significant differences between the dabigatrane and rivoraxaban groups in terms of age, gender, treatment-duration, concomitant use of antiplatelets, CHADS-VASc score and HAS-BLED score. The frequency of chronic atrial fibrillation was significantly higher in rivoraxaban group compared to dabigatrane group. (rivaroxaban:62/88; dabigatran 46/95; p<0,005). The mean age was significantly higher in the low dose groups of both of the drugs. (Figure)(66±7 vs. 74±9 for dabigatran 150 mg and 110 mg subsequently, p:0,0005; 68±8 vs. 77±7 for rivaroxaban 20 mg and 20 mg subsequently; p<0,0001). The clinical events occured in the usage period of dabigatrane and rivoraxaban were summarized in the table. One tromboembolic cerebrovascular accident occurred in the rivaroxaban 15 mg group. Fifteen patients died during follow-up. Ten of them were in dabigatrane group and 5 were in the rivoraxaban group. It has been detected 1 intracranial hemorrage in the dabigatrane group and 1 subdural hematoma in rivoraxaban group. It has been detected 7 gastrointestinal hemorrhage in the dabigatrane group and 4 gastrointestinal hemorrhage in the rivoraxaban group. There were 10 minor hemorrhages in the dabigatrane group and 14 minor hemorrhages in the rivoraxaban group. There were no statistically significant difference between dabigatran and rivaroxaban groups in terms of thromboembolic events and hemorrhagic complications.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
